Clinical Trials and Research

AbstractWild-type transthyretin amyloid (ATTRwt) amyloidosis is a systemic, progressive disease that often affects older adults and is characterized by ATTRwt…

Cardiac amyloidosis is an increasingly recognized infiltrative cardiomyopathy characterized by extracellular deposition of misfolded amyloid fibrils within the…

AbstractBackground: Acoramidis, an oral transthyretin stabilizer that achieves near-complete (≥90%) transthyretin stabilization, demonstrated significant clinical…

AbstractCardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy most commonly caused by transthyretin (ATTR) or immunoglobulin light chain (AL)…

Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease characterized by the accumulation of misfolded transthyretin amyloid proteins in the…

AbstractAcute heart failure (AHF) represents a major global health challenge, with a substantial impact on survival, morbidity, and health care resource utilization…

AbstractBACKGROUND:Cardiac amyloidosis (CA) is an underdiagnosed yet treatable cause of heart failure in which timely diagnosis is essential to initiate life-…

AbstractBackground and ObjectiveWe assessed the consistency of serum transthyretin (TTR) knockdown with the RNA interference therapeutic vutrisiran across…

AbstractSystemic amyloid light-chain (AL) amyloidosis is a multisystem disorder caused by extracellular deposition of monoclonal immunoglobulin light chains.…

AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt) is an underrecognized cause of heart failure that often mimics hypertensive or nonischemic…